Evaluation and Posttest
To enable us to maintain the highest scientific and educational standards when planning future activities, we would appreciate your evaluation of this activity and its content. Please select the appropriate rating numbers and add your comments for the evaluation. Please also select the best answers to the posttest questions below.



Patient outcomes could be measurably improved if physicians were better able to…

Differentiate between male and female osteoporosis, understanding that, although prevalence is lower in men, they are at increased risk for hip fracture and mortality

Recognize that increased clinical vigilance for both osteoporosis and hypogonadism will lead to improved healthcare outcomes

Diagnose and evaluate symptoms of hypogonadism and osteoporosis

Review treatment options that will improve hypogonadism and low bone mineral density


This activity:

Met my expectations

Was relevant to my clinical practice

Was presented without commercial bias

Used an appropriate teaching method


After participating in this activity, I will change my clinical practice by:

What related topics would you like to see offered in future CME activities?

Additional comments:

Thank you.

*I hereby certify that I have spent hour(s) on this educational activity.


1. Zacharin and colleagues assessed bone mineral density (BMD) in hypogonadal men receiving long-term long-acting testosterone therapy in a cross-sectional study of 37 patients. Testosterone therapy resulted in ______.
 Adequate bone mass accumulation
 Maintenance of normal BMD
 Increased incidence of jaw osteonecrosis
 Adequate bone mass accumulation and maintenance of normal BMD

2. Males with hypogonadism are ______ times more likely to have minimal-trauma hip fractures than are age-matched control participants.

3. After the age of 50 years, 1 in ______ osteoporotic fractures occur in men.

4. To date, studies of testosterone therapy in men with osteoporosis are limited and do not use ______ as a primary endpoint.
 Walking distance
 Fracture Risk Assessment Tool (FRAX)


© 2011 CogniMed Inc. All rights reserved.            TU13127/ACHS 4840             November 2011